12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Gilead, Japan Tobacco deal

Gilead granted Japan Tobacco exclusive rights in Japan to develop and commercialize cobicistat. Cobicistat, an inhibitor of cytochrome P450 family 3 subfamily A ( CYP3A), is in Phase III...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >